Ultragenyx Pharmaceutical Inc.
$17.8M 2,488 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
CSL Plasma Inc.
CSL Plasma Inc. reported $17,902,114.58 across General Payments, Research, and Ownership to 12,905 physicians and teaching hospitals across 12,905 transactions.
- $17.9M Top 10% payer
- All-tracks total
- 12,905 Top 10% volume
- Transactions
- 12,905 Top 10% reach
- Recipients
- +$2.1M
- General Payments vs PY2023
CSL Plasma Inc. reported $17,902,114.58 across all CMS Open Payments tracks (General + Research + Ownership) to 12,905 physicians and teaching hospitals in Program Year 2024 - ranking #101 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $17,902,114.58, averaging $1.4K per recipient.
CSL Plasma Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
78/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer csl-plasma-inc CSL Plasma Inc.
$17.9M · #101/1,925 · 0.1% industry · PY2024
- TOT $17.9M
- RANK #101
- SHARE 0.1%
- TXN 12,905
- RCP 12,905
- CAT 1
- GEN $17.9M
- ΔGEN +$2.1M
- TOP1 4.5%
- PY 2024
Volume peers
Nearest volume peer: Ultragenyx Pharmaceutical Inc. ($17.8M)
CSL Plasma Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
CSL Plasma Inc.'s CMS-reported General Payments increased by $2.1M (+13.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: CSL PLASMA INC.PY2024: CSL Plasma Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $15,772,621.77
- PY2024
- $17,902,114.58
What the Data Shows for CSL Plasma Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For CSL Plasma Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
12,905 transactions worth $17.9M make "Consulting Fee" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, CSL Plasma Inc.'s largest category was "Consulting Fee" at $17.9M - 100.0% of General Payments.
How CSL Plasma Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $17.9M | 12,905 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,368,120.54 (13.2%) of $17,902,114.58 in this company's General Payments records across 262 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for CSL Plasma Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Majed Refaai
$807,450.00 across 125 reported transactions
- 2
Jennifer Parsley
$415,425.00 across 76 reported transactions
- 3
Christina Samathanam
$400,657.32 across 190 reported transactions
- 4
Michael Gibson
$388,260.72 across 274 reported transactions
- 5
John Mckinney
$356,327.50 across 133 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
CSL Plasma Inc. ranks #101 of 1,925 by total payments (top 5% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,690 of 1,838 by HHI (bottom 8% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Almatica Pharma LLC : $421.9K total payments, HHI 106
- Vifor Pharma, Inc. : $368.6K total payments, HHI 106
- Grifols USA, LLC : $2.0M total payments, HHI 105
- Neurelis, Inc. : $1.9M total payments, HHI 104
- ACADIA Pharmaceuticals Inc : $2.6M total payments, HHI 102
- Biotronik Inc. : $2.4M total payments, HHI 102
- CSL Plasma Inc. (this company) : $17.9M total payments, HHI 100
- Ardelyx, Inc. : $1.8M total payments, HHI 99
- Synthes GmbH : $2.5M total payments, HHI 99
- ANI Pharmaceuticals, Inc. : $1.1M total payments, HHI 98
- Arcutis Biotherapeutics, Inc. : $5.0M total payments, HHI 97
- CVRx, Inc. : $1.5M total payments, HHI 97
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as CSL Plasma Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about CSL Plasma Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with CSL Plasma Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Becton, Dickinson and Company
$17.8M 12,620 recipients
Compare payment profiles
Spinecraft, LLC
$18.2M 27 recipients
Compare payment profiles
Taiho Oncology, Inc.
$17.6M 5,970 recipients
Compare payment profiles
Sun Pharmaceutical Industries Inc.
$18.3M 77,951 recipients
Compare payment profiles
UCB, Inc.
$18.5M 154,022 recipients
Compare payment profiles
Put this to use
CSL Plasma Inc. ranks #101 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where CSL Plasma Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just CSL Plasma Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.